Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Carsgen Therapeutics Co. Ltd. maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. Juliana Irene Candelaria is the busiest examiner, handling the 1 pending office action currently on record.
This profile reflects a targeted approach to biotechnology patenting with a single point of contact at the patent office for the company's current filings. Practitioners should note that the current examination is confined to 1 art unit, which may simplify the coordination of prosecution strategies. This focused distribution reflects a specific technological scope for the company's current patenting efforts. The alignment of the workload under a single examiner indicates a narrow point of contact within the patent office. The absence of multiple pending matters suggests that the company is prioritizing specific innovations within the Biotechnology & Pharmaceuticals sector. Such a concentrated profile may result in more predictable prosecution timelines compared to portfolios spread across numerous art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18908061 | METHOD FOR TREATING TUMOR USING IMMUNE CELL | CANDELARIA, JULIANA IRENE | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18908061 | METHOD FOR TREATING TUMOR USING IMMUNE CELL | CANDELARIA, JULIANA IRENE | 1634 | §102§103§112DP | Non-Final OA | — | Pending | Oct 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCarsgen Therapeutics Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Juliana Irene Candelaria has the most, with 1 of Carsgen Therapeutics Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
